Neuren PharmaceuticalsNURPF +6.67%49 Net Margin % is 42.37% as of Dec. 2025, which is 10% below its 10-year median of 47.09. GuruFocus rates NURPF with a GF Score™ of 49/100 and a GF Value™ of $4.40 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, Neuren Pharmaceuticals ranks better than 94.82% on this metric.
The historical rank and industry rank for Neuren Pharmaceuticals's Net Margin % or its related term are showing as below:
NURPF'
s Net Margin % Range Over the Past 10 Years
Min: 1.26 Med: 47.09 Max: 67.73
Current: 47.09
NURPF's Net Margin % is ranked better than 94.82% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs NURPF: 47.09
Neuren Pharmaceuticals (OTCPK:NURPF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Neuren Pharmaceuticals Net Margin % Related Terms
Neuren Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NURPF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Neuren Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (NURPF) has a Net Margin % of 42.37% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Neuren Pharmaceuticals and its competitors. This is 10% below median its historical median of 47.09. Over the past decade, Neuren Pharmaceuticals' Net Margin % has ranged from 1.26 to 67.73. According to the industry distribution chart, Neuren Pharmaceuticals ranks #49 out of 946 companies in the Biotechnology industry, placing it in the top 5.2%.
Is Neuren Pharmaceuticals' Net Margin % too high?
Neuren Pharmaceuticals' current Net Margin % of 42.37% is 10% below median its 10-year median of 47.09. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 67.73. Based on the distribution chart, Neuren Pharmaceuticals ranks #49 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #49 out of 946 companies for Net Margin %. This places Neuren Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. Historically, Neuren Pharmaceuticals' own Net Margin % has ranged from 1.26 to 67.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Net Margin % is 42.37%, which is 10% below median its own 10-year median of 47.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (NURPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.40, compared to a current price of $9.27 — trading 110.7% above its estimated fair value. The current Net Margin % is 42.37%, which is 10% below median its 10-year median of 47.09. Neuren Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Neuren Pharmaceuticals (NURPF), the current Net Margin % is 42.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (NURPF) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of $9.27 is trading 110.7% above its estimated GF Value™ of $4.40.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NURPF:
Net Margin %: 42.37% (10% below median its 10-year median of 47.09)
GF Value™: $4.40 vs. price of $9.27 (110.7% above fair value)
No single metric tells the full story. See the NURPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
49GF Score
Get the complete analysis for NURPF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NURPF has been successfully added to your 
